NASDAQ · PHARMACEUTICAL PREPARATIONS
Rani Therapeutics Holdings, Inc. RANI
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.6M
▲ 58.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-169.6%
Net margin · FY25
-1817.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.6M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 1817 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-169.6%
Return on equity, FY2025
ROE
Operating margin-2346.0%
Net margin-1817.1%
Return on assets-62.3%
Each USD of equity lost 170 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+28.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+28.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 58.6M
total assets, end of FY2025
Total assetsUSD 58.6M
EquityUSD 33.0M
CashUSD 18.6M
Gross debtUSD 0.00
Net debtUSD -18.6M
Current ratio4.21×
The company holds more cash than debt.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−169.6
−404.1
−136.6
−72.6
·
·
Shares out B
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
17 of 17
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed